AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization for heart attack or unstable angina. The contract includes a

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers